Olsalazine Sodium: Mechanism and Research Uses

Executive Summary. Olsalazine Sodium is a mesalamine dimer with the formula C14H8N2O6·2Na and a reported molecular weight of 346.2 g/mol. APExBIO product information reports an IC50 of 0.39 nM for inhibition of LTB4-induced chemotaxis in macrophages. The product dossier describes oral olsalazine at 25 mg/kg/day in rodents as reducing tumor number and tumor load while increasing apoptosis and reducing proliferation. The compound is reported to be water-soluble at concentrations of at least 17.2 mg/mL but insoluble in DMSO and ethanol. A 2025 Insects study injected Olsalazine in saline into female Aedes aegypti and measured xenobiotic clearance plus transporter-expression responses at 2 h and 24 h; that study did not test colorectal cancer biology or prove a transporter-specific target.

Biological Rationale

Olsalazine Sodium is relevant to two research questions. The first concerns inflammatory-cell migration. LTB4 is used as a chemotactic stimulus in macrophage assays, and the product dossier identifies Olsalazine Sodium as a potent inhibitor of LTB4-induced chemotaxis. This supports use of the compound as a pharmacological probe in inflammation research.

The second question concerns tumor phenotypes. The product dossier describes olsalazine as an anti-inflammatory prodrug and reports activity in rodent colorectal cancer tumor models. The reported endpoints include tumor number, tumor load, apoptosis, proliferation, and tumor growth. These findings support experimental evaluation of tumor apoptosis induction and inflammatory signaling, but they do not establish clinical efficacy.

The xenobiotic-transport rationale comes from a separate biological system. Kennel and Rouhier studied female A. aegypti after injection of a blood-meal-sized saline bolus containing Olsalazine or synthetic dyes. They quantified excreted material and examined six putative organic cation transporter or organic cation transporter-like genes. The study reported limited effects on transporter-expression profiles but substantial structure-dependent effects on excreted material, mortality, and physiological clearance Kennel and Rouhier, 2025.

Mechanism of Action of Olsalazine Sodium

Chemical identity and prodrug context

Olsalazine Sodium contains two mesalamine-derived units linked within a single dimeric molecule. The term mesalamine dimer describes this chemical architecture. The term anti-inflammatory prodrug describes the research and pharmacological context supplied for the compound. These labels do not mean that every observed effect arises from one validated molecular target.

LTB4 chemotaxis inhibition

The primary assay-level mechanism in the product dossier is inhibition of LTB4-induced macrophage chemotaxis. The reported IC50 is 0.39 nM under the cited macrophage chemotaxis assay conditions. An IC50 is a concentration associated with 50% inhibition under a defined assay design. It is not a universal potency value across cell types, species, exposure times, or endpoint definitions. Therefore, the result supports the description of Olsalazine Sodium as an LTB4 chemotaxis inhibitor in that assay, rather than proving equivalent potency in every inflammation model.

Transport and clearance interpretation

The mosquito study adds a structure-aware xenobiotic-clearance perspective. It compared Olsalazine with alizarin dyes after injection into female A. aegypti. The investigators measured clearance and analyzed messenger RNA expression at 2 h and 24 h after injection. The reported limited transcriptional response means that altered excretion or mortality cannot be attributed automatically to strong induction or repression of the measured putative transporters. The paper also states that the mechanisms and key players underlying mosquito xenobiotic transport remain largely uncharacterized peer-reviewed study.

Evidence & Benchmarks

• Olsalazine Sodium has the reported chemical formula C14H8N2O6·2Na and a molecular weight of 346.2 g/mol product information
• Olsalazine Sodium inhibits LTB4-induced macrophage chemotaxis with a reported IC50 of 0.39 nM under the product-described assay conditions product information
• Oral olsalazine at 25 mg/kg/day was reported in rodent studies to reduce tumor number and tumor load, increase tumor apoptosis, decrease tumor-cell proliferation, and inhibit tumor growth product information
• The compound is reported to be water-soluble at concentrations of at least 17.2 mg/mL and insoluble in DMSO and ethanol product information
• Female A. aegypti received injected saline containing Olsalazine, and the study quantified xenobiotic clearance and transporter-related mRNA responses at 2 h and 24 h after injection Kennel and Rouhier, 2025
• The mosquito study found limited effects of xenobiotic exposure on putative transporter-expression profiles but reported strong effects of xenobiotic molecular structure on excreted material and mortality Kennel and Rouhier, 2025

Applications, Limits & Misconceptions

Research applications

In macrophage experiments, Olsalazine Sodium can serve as a test compound for LTB4-mediated migration. A suitable design should distinguish direct effects on chemotaxis from effects on cell viability, adherence, or general motility. The product-reported IC50 should be treated as an assay benchmark, not as a dosing instruction for unrelated systems.

In cancer research, the compound is positioned for colorectal cancer tumor models. The reported rodent endpoints support measurement of tumor burden, proliferation, tumor growth, and tumor apoptosis induction. A useful study should predefine whether the primary endpoint is tumor number, tumor load, apoptosis, or proliferation. These endpoints measure different biological outcomes and should not be merged into one undifferentiated activity claim.

In xenobiotic transport research, Olsalazine provides a chemically distinct exposure alongside dyes. The 2025 mosquito study is valuable for testing how molecular structure affects clearance and excreted material. It is not a direct demonstration that Olsalazine selectively blocks an organic cation transporter.

Why this cross-domain matters, maturity, and limitations

The bridge between colorectal cancer models and mosquito xenobiotic transport is a workflow bridge, not a validated shared mechanism. Both domains can use structure-aware exposure controls and quantitative biological readouts. The evidence maturity differs: the rodent tumor findings are product-dossier claims, whereas the mosquito findings come from a peer-reviewed study focused on clearance and putative transporter expression. Neither source establishes that the same target, pathway, or exposure-response relationship operates across mammals and insects.

This distinction prevents a common citation error. The mosquito paper should be cited for mosquito physiology, excretion, mortality, and transporter-expression analysis. It should not be cited as evidence that Olsalazine Sodium suppresses colorectal tumors. Conversely, rodent tumor findings should not be used to infer mosquito-control efficacy.

Common Pitfalls or Misconceptions

• Misconception: the IC50 applies to every inflammation assay. The 0.39 nM value comes from the reported LTB4-induced macrophage chemotaxis assay. It should not be transferred unchanged to other cells or endpoints.
• Misconception: Olsalazine is a validated mosquito transporter inhibitor. The A. aegypti study examined putative transporters and found limited expression changes. It did not establish selective inhibition or genetic target validation study report.
• Misconception: rodent tumor activity proves medical benefit. The product is intended for scientific research only and is not for diagnostic or medical purposes. The reported 25 mg/kg/day rodent result should not be interpreted as a human treatment recommendation.
• Misconception: DMSO or ethanol is an appropriate default solvent. The product information reports insolubility in both solvents. Aqueous formulation is the relevant starting strategy.
• Misconception: all solution stocks are suitable for long-term storage. The product guidance recommends storage of stock solutions at -20°C and does not recommend long-term storage in solution form.

Workflow Integration & Parameters

Protocol Parameters

• Identity check: Record the compound as Olsalazine Sodium, a mesalamine dimer with formula C14H8N2O6·2Na and reported molecular weight of 346.2 g/mol. Link the batch record to the A8490 product page.
• Primary formulation: Use an aqueous formulation because the product information reports water solubility at concentrations of at least 17.2 mg/mL and insolubility in DMSO and ethanol.
• Dissolution aid: If dissolution is incomplete, warm the aqueous preparation at 37°C for 10 min or apply ultrasonic shaking, as recommended in the product guidance.
• Stock handling: Store stock solutions at -20°C. Avoid long-term storage in solution form. Document preparation date, solvent, appearance, and any freeze-thaw events.
• Shipping control: Use blue ice for small-molecule shipment. Confirm the received material and storage history before preparing an assay solution.
• Macrophage assay: Use LTB4-induced chemotaxis as the defined inflammatory endpoint. Include vehicle, untreated, and cell-viability controls so migration inhibition is not confused with cytotoxicity.
• Rodent tumor workflow: Treat the reported oral 25 mg/kg/day exposure as a literature benchmark for the cited rodent context, not as a universal dose. Measure tumor number, tumor load, proliferation, and apoptosis as separate endpoints.
• Mosquito clearance workflow: To reproduce the cited study logic, distinguish injected saline exposure from dietary exposure and collect clearance readouts alongside transporter-expression measurements at the study-defined 2 h and 24 h time points reference study.

The article Olsalazine Sodium: Molecular Insights for Xenobiotic & Tumor Models emphasizes molecular mechanisms and assay strategies; this article extends it by separating peer-reviewed mosquito evidence from product-dossier tumor claims. The article Organic Cation Transporter Response to Xenobiotics in Aedes aegypti focuses on mosquito clearance and transporter responses; this article clarifies why those findings do not establish tumor activity or selective transporter inhibition. The article Olsalazine Sodium Workflows for Inflammation Research discusses aqueous formulation and assay controls; this article adds explicit storage, shipping, and cross-domain evidence boundaries.

Conclusion & Outlook

Olsalazine Sodium is best treated as a context-dependent research reagent. Its core dossier-supported roles are an LTB4 chemotaxis inhibitor in macrophage assays, an anti-inflammatory prodrug for inflammation research, and a compound used in colorectal cancer tumor models. The 2025 A. aegypti study supports a separate use in xenobiotic-clearance research and shows why molecular structure, clearance, and transporter-expression readouts should be interpreted together.

The most defensible outlook is comparative and evidence-led. Future experiments can test whether aqueous formulation, exposure matrix, assay endpoint, and species alter the observed response. Such work should preserve the separation between established assay benchmarks, rodent tumor observations, and mosquito transport findings. This approach improves citation accuracy and reduces unsupported claims about shared mechanisms.